Abstract

In this study, we investigated the tumor targeting effect in cancer cells using triphenylphosphonium (TPP) cations, which are accumulated by differences in membrane potential, and folic acid (FA), which is selectively bound to overexpressed receptors on various cancer cells. We used Food and Drug Administration (FDA)-approved silica nanoparticles (SNPs) as drug carriers, and SNPs conjugated with TPP and FA (STFs) samples were prepared by introducing different amounts of TPP and FA onto the nanoparticle surfaces. STF-1, 2, 3, 4 and 5 are named according to the combination ratio of TPP and FA on the particle surface. To confirm the tumor targeting effect, 89Zr (t1/2 = 3.3 days) was coordinated directly to the silanol group of SNP surfaces without chelators. It was shown that the radiochemical yield was 69% and radiochemical purity was >99%. In the cellular uptake evaluation, SNPs with the most TPP (SFT-5) and FA (SFT-1) attached indicated similar uptake tendencies for mouse colon cancer cells (CT-26). However, the results of the cell internalization assay and measurement of positron emission tomography (PET) images showed that SFT-5 had more affinity for the CT-26 tumor than other samples the TPP ratio of which was lower. Consequently, we confirmed that TPP ligands affect target cancer cells more than FA, which means that cell membrane potential is significantly effective for tumor targeting.

Highlights

  • Triphenylphosphonium (TPP) cations are lipophilic cations that can target cancer cells through the membrane potential of cancer cells [1,2]

  • silica nanoparticles (SNPs) were synthesized by the method of Stöber and analyzed by FT-IR and an Scanning electron microscope (SEM)

  • TPP and folic acid (FA) were bound to SNPs at different ratios, and 89 Zr was labeled to observe the cell uptake of the samples and positron emission tomography (PET) imaging over time

Read more

Summary

Introduction

Triphenylphosphonium (TPP) cations are lipophilic cations that can target cancer cells through the membrane potential of cancer cells [1,2]. Mitochondria in cancer cells are known to have a membrane potential difference of about 60 mV from normal cells due to abnormal metabolic behavior, and 10 times more TPP accumulates in the mitochondria of cancer cells due to this difference [6,7,8]. Expressed on the cell membrane in the body [9,10,11]. FA and FA complexes show high affinity (Kd ~ 10−9 M) for FR-α and FR-β and are endogenous to FR-expressing cells because of their receptor-mediated endocytosis

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.